122 related articles for article (PubMed ID: 38903535)
1. The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program.
Fagnan A; Aid Z; Baille M; Drakul A; Robert E; Lopez CK; Thirant C; Lecluse Y; Rivière J; Ignacimouttou C; Salmoiraghi S; Anguita E; Naimo A; Marzac C; Pflumio F; Malinge S; Wichmann C; Huang Y; Lobry C; Chaumeil J; Soler E; Bourquin JP; Nerlov C; Bernard OA; Schwaller J; Mercher T
Hemasphere; 2024 Jun; 8(6):e90. PubMed ID: 38903535
[TBL] [Abstract][Full Text] [Related]
2. A direct comparison between AML1-ETO and ETO2-GLIS2 leukemia fusion proteins reveals context-dependent binding and regulation of target genes and opposite functions in cell differentiation.
Zhang YF; Wang XL; Xu CH; Liu N; Zhang L; Zhang YM; Xie YY; Zhang YL; Huang QH; Wang L; Chen Z; Chen SJ; Roeder RG; Shen S; Xue K; Sun XJ
Front Cell Dev Biol; 2022; 10():992714. PubMed ID: 36158200
[TBL] [Abstract][Full Text] [Related]
3. Eto2/MTG16 and MTGR1 are heteromeric corepressors of the TAL1/SCL transcription factor in murine erythroid progenitors.
Cai Y; Xu Z; Xie J; Ham AJ; Koury MJ; Hiebert SW; Brandt SJ
Biochem Biophys Res Commun; 2009 Dec; 390(2):295-301. PubMed ID: 19799863
[TBL] [Abstract][Full Text] [Related]
4. High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia.
Aid Z; Robert E; Lopez CK; Bourgoin M; Boudia F; Le Mene M; Riviere J; Baille M; Benbarche S; Renou L; Fagnan A; Thirant C; Federici L; Touchard L; Lecluse Y; Jetten A; Geoerger B; Lapillonne H; Solary E; Gaudry M; Meshinchi S; Pflumio F; Auberger P; Lobry C; Petit A; Jacquel A; Mercher T
Leukemia; 2023 Mar; 37(3):571-579. PubMed ID: 36585521
[TBL] [Abstract][Full Text] [Related]
5. ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.
Thirant C; Ignacimouttou C; Lopez CK; Diop M; Le Mouël L; Thiollier C; Siret A; Dessen P; Aid Z; Rivière J; Rameau P; Lefebvre C; Khaled M; Leverger G; Ballerini P; Petit A; Raslova H; Carmichael CL; Kile BT; Soler E; Crispino JD; Wichmann C; Pflumio F; Schwaller J; Vainchenker W; Lobry C; Droin N; Bernard OA; Malinge S; Mercher T
Cancer Cell; 2017 Mar; 31(3):452-465. PubMed ID: 28292442
[TBL] [Abstract][Full Text] [Related]
6. The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53.
Piqué-Borràs MR; Jevtic Z; Bagger FO; Seguin J; Sivalingam R; Bezerra MF; Louwagie A; Juge S; Nellas I; Ivanek R; Tzankov A; Moll UM; Cantillo O; Schulz-Heddergott R; Fagnan A; Mercher T; Schwaller J
Blood; 2023 May; 141(18):2245-2260. PubMed ID: 36735909
[TBL] [Abstract][Full Text] [Related]
7. Embryonic erythropoiesis and hemoglobin switching require transcriptional repressor ETO2 to modulate chromatin organization.
Guo X; Plank-Bazinet J; Krivega I; Dale RK; Dean A
Nucleic Acids Res; 2020 Oct; 48(18):10226-10240. PubMed ID: 32960220
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways driven by ETO2-GLIS2 in aggressive pediatric leukemia.
Thirant C; Lopez C; Malinge S; Mercher T
Mol Cell Oncol; 2017; 4(6):e1345351. PubMed ID: 29209645
[TBL] [Abstract][Full Text] [Related]
9. The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability.
Huang Y; Mouttet B; Warnatz HJ; Risch T; Rietmann F; Frommelt F; Ngo QA; Dobay MP; Marovca B; Jenni S; Tsai YC; Matzk S; Amstislavskiy V; Schrappe M; Stanulla M; Gstaiger M; Bornhauser B; Yaspo ML; Bourquin JP
Cancer Cell; 2019 Dec; 36(6):630-644.e9. PubMed ID: 31735627
[TBL] [Abstract][Full Text] [Related]
10. CTCF: A novel fusion partner of ETO2 in a multiple relapsed acute myeloid leukemia patient.
Li J; Shen Z; Wang Z; Chao H; Xu Y; Zeng Z; Bian X; Zhang J; Pan J; Miao W; Wu W; Yao L; Chen S; Wen L
J Leukoc Biol; 2022 May; 111(5):981-987. PubMed ID: 34622967
[TBL] [Abstract][Full Text] [Related]
11. Screening of ETO2-GLIS2-induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemia.
Benbarche S; Lopez CK; Salataj E; Aid Z; Thirant C; Laiguillon MC; Lecourt S; Belloucif Y; Vaganay C; Antonini M; Hu J; da Silva Babinet A; Ndiaye-Lobry D; Pardieu B; Petit A; Puissant A; Chaumeil J; Mercher T; Lobry C
Sci Adv; 2022 Feb; 8(6):eabg9455. PubMed ID: 35138899
[TBL] [Abstract][Full Text] [Related]
12. Integrated genome-wide chromatin occupancy and expression analyses identify key myeloid pro-differentiation transcription factors repressed by Myb.
Zhao L; Glazov EA; Pattabiraman DR; Al-Owaidi F; Zhang P; Brown MA; Leo PJ; Gonda TJ
Nucleic Acids Res; 2011 Jun; 39(11):4664-79. PubMed ID: 21317192
[TBL] [Abstract][Full Text] [Related]
13. The transcriptional corepressor CBFA2T3 inhibits all-
Steinauer N; Guo C; Zhang J
J Biol Chem; 2020 Jul; 295(27):8887-8900. PubMed ID: 32434928
[TBL] [Abstract][Full Text] [Related]
14. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347
[TBL] [Abstract][Full Text] [Related]
15. Role of transcriptional corepressor ETO2 in erythroid cells.
Fujiwara T; Alqadi YW; Okitsu Y; Fukuhara N; Onishi Y; Ishizawa K; Harigae H
Exp Hematol; 2013 Mar; 41(3):303-15.e1. PubMed ID: 23127762
[TBL] [Abstract][Full Text] [Related]
16. Characterization of megakaryocyte GATA1-interacting proteins: the corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation.
Hamlett I; Draper J; Strouboulis J; Iborra F; Porcher C; Vyas P
Blood; 2008 Oct; 112(7):2738-49. PubMed ID: 18625887
[TBL] [Abstract][Full Text] [Related]
17. The pioneer factor activity of c-Myb involves recruitment of p300 and induction of histone acetylation followed by acetylation-induced chromatin dissociation.
Fuglerud BM; Ledsaak M; Rogne M; Eskeland R; Gabrielsen OS
Epigenetics Chromatin; 2018 Jun; 11(1):35. PubMed ID: 29954426
[TBL] [Abstract][Full Text] [Related]
18. The mechanism of MYB transcriptional regulation by MLL-AF9 oncoprotein.
Cao L; Mitra P; Gonda TJ
Sci Rep; 2019 Dec; 9(1):20084. PubMed ID: 31882723
[TBL] [Abstract][Full Text] [Related]
19. The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression.
Coulibaly A; Haas A; Steinmann S; Jakobs A; Schmidt TJ; Klempnauer KH
PLoS One; 2018; 13(2):e0190934. PubMed ID: 29394256
[TBL] [Abstract][Full Text] [Related]
20. Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia.
Lopez CK; Noguera E; Stavropoulou V; Robert E; Aid Z; Ballerini P; Bilhou-Nabera C; Lapillonne H; Boudia F; Thirant C; Fagnan A; Arcangeli ML; Kinston SJ; Diop M; Job B; Lecluse Y; Brunet E; Babin L; Villeval JL; Delabesse E; Peters AHFM; Vainchenker W; Gaudry M; Masetti R; Locatelli F; Malinge S; Nerlov C; Droin N; Lobry C; Godin I; Bernard OA; Göttgens B; Petit A; Pflumio F; Schwaller J; Mercher T
Cancer Discov; 2019 Dec; 9(12):1736-1753. PubMed ID: 31662298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
